Keyphrases
Alemtuzumab
100%
Alloactivation
25%
Allospecific
100%
CD127
25%
CD25
25%
CD4 Cells
12%
CD4+
37%
Cell Generation
100%
Cell Subsets
12%
Drug Addition
12%
Flow Cytometry
12%
Fluorescein Diacetate
12%
FoxP3+
12%
Healthy Volunteers
12%
HLA-DR
12%
Human Complement
12%
Immunoregulation
12%
Lymphodepletion
12%
Lymphoproliferation
37%
Mixed Lymphocyte Reaction
62%
Nave
12%
Peripheral Blood
12%
Presensitization
12%
Refractoriness
12%
Regulatory T (Treg) Cells
62%
Regulatory T Cells
100%
Sirolimus
25%
T Cells
12%
Tacrolimus
12%
Treg
12%
Immunology and Microbiology
Alemtuzumab
100%
CD25
25%
CD4
50%
FOXP3
12%
Human Leukocyte Antigen
12%
Immunoregulation
12%
Lymphocyte Proliferation
37%
Mixed Lymphocyte Reaction
62%
Normal Human
12%
Regulatory T Cell
100%
Sirolimus
25%
T Cell
12%
Tacrolimus
12%